News for Flexion Therapeutics Inc (F02.F)

BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees

Today's Daily Dose brings you news about the progress in Flexion Therapeutics' pipeline; Immunome's coronavirus research program; Pfizer/BioNTech testing COVID-19 vaccine in pregnant women; and Rigel's deal with Lilly to develop RIPK1 inhibitors.

First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety data Company ...

Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 milli...

Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 million

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and ...